NAMS compared with MIRM: revenue, margins and what each company keeps, and the suppliers and customers both name

NAMSNewAmsterdam Pharma Co N.V.

Mkt capRevenueRevenue

MIRMMirum Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

NAMSNewAmsterdam Pharma Co N.V.

MIRMMirum Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NAMS1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.6%▼−0.47%×0.04

MIRM

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±9.3%▼−11.04%×1.18

May 7 '26±6.1%▼−6.50%×1.07

= impliedNAMS realized, solidMIRM realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedSource: market data

Q1 FY26

±6.9%

▼−15.13%

×2.19

Jan 12 '26±7.1%▲+3.38%×0.48

NAMSNewAmsterdam Pharma Co N.V.

19.57▼−2.43%· post 19.57

Mkt cap$2.4BRevenue$4MQ2 FY26Revenue$23MFY25

MIRMMirum Pharmaceuticals, Inc.

85.49▲+0.58%· post 85.82

ClosedNov 2 '26

Mkt cap$5.6BRevenue$176MQ2 FY26Revenue$521MFY25

Compare

ClosedNov 2 '26

NAMSNewAmsterdam Pharma Co N.V.

MIRMMirum Pharmaceuticals, Inc.

19.57▼−2.43%post 19.57

Price

85.49▲+0.58%post 85.82

$2.4B

Mkt cap

$5.6B

Q2 FY26$4M

Revenue

$176MQ2 FY26

FY25$23M

Revenue

$521MFY25

NAMS19.57▼−2.43%vsMIRM85.49▲+0.58%ClosedNov 2 '26